Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Wakamoto Grants North American Rights for MaQaid to Harrow
August 19, 2021
- Otsuka Wins Japan Approval for OD Tablet Form of Rexulti
August 19, 2021
- 1st Drug for Short Bowel Syndrome Now Available in Japan: Takeda
August 19, 2021
- Sawai to Suspend Shipments of Loperamide Capsules after Foreign Matter Identified
August 19, 2021
- Nichi-Iko, Medipal Form Capital Tie-Up; 5.2 Billion Yen Investment Goes towards CapEx
August 18, 2021
- MSD to Lift Shipment Restrictions on Pneumovax
August 18, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- Choseido Likely to Face Administrative Penalty over Manufacturing Flaws
August 18, 2021
- 1st Patient Dosed in Multinational PII Study of Brincidofovir: SymBio
August 18, 2021
- AbbVie to Begin Clinical Development of Schizophrenia Drug in Japan
August 18, 2021
- Japan Pharma Market Delivers 1st Growth in 5 Qtrs in April-June: IQVIA
August 18, 2021
- Teva Takeda Set to Roll Out 2nd Blopress AG but Denies Competition with ASKA
August 17, 2021
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
- OBP-601 to Enter US PII for Neurodegenerative Diseases: Oncolys
August 17, 2021
- Boehringer Joins NCC’s Rare Cancer Project
August 16, 2021
- Sandoz Curbs Shipments of Leprosy Drug, Hints at Supply Halt
August 16, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- Ono, MiraBiologics Ink Biologics Discovery Deal
August 16, 2021
- Towa’s Shipment Restriction List Now Expands to 352 Products
August 16, 2021
- Evrysdi, Aimovig Now Available; Veklury’s Normal Distribution to Start around October
August 13, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…